Unknown

Dataset Information

0

The University of Zimbabwe College of Health Sciences (UZ-CHS) BIRTH COHORT study: rationale, design and methods.


ABSTRACT: BACKGROUND:Commencing lifelong antiretroviral therapy (ART) immediately following HIV diagnosis (Option B+), has greatly improved maternal-infant health. Thus, large and increasing numbers of HIV-infected women are on ART during pregnancy, a situation concurrently increasing numbers of HIV-exposed-uninfected (HEU) infants. Compared to their HIV-unexposed-uninfected (HUU) counterparts, HEU infants show higher rates of adverse birth outcomes, mortality, infectious/non-communicable diseases including impaired growth and neurocognitive development. There is an urgent need to understand the impact of HIV and early life ART exposures, immune-metabolic dysregulation, comorbidities and environmental confounders on adverse paediatric outcomes. METHODS:Six hundred (600) HIV-infected and 600 HIV-uninfected pregnant women ?20?weeks of gestation will be enrolled from four primary health centres in high density residential areas of Harare. Participants will be followed up as mother-infant-pairs at delivery, week(s) 1, 6, 10, 14, 24, 36, 48, 72 and 96 after birth. Clinical, socio-economic, nutritional and environmental data will be assessed for adverse birth outcomes, impaired growth, immune/neurodevelopment, vertical transmission of HIV, hepatitis-B/C viruses, cytomegalovirus and syphilis. Maternal urine, stool, plasma, cord blood, amniotic fluid, placenta and milk including infant plasma, dried blood spot and stool will be collected at enrolment and follow-up visits. The composite primary endpoint is stillbirth and infant mortality within the first two years of life in HEU versus HUU infants. Maternal mortality in HIV-infected versus -uninfected women is another primary outcome. Secondary endpoints include a range of maternal and infant outcomes. Sub-studies will address maternal stress and malnutrition, maternal-infant latent tuberculosis, Helicobacter pylori infections, immune-metabolomic dysregulation including gut, breast milk and amniotic fluid dysbiosis. DISCUSSION:The University of Zimbabwe-College of Health-Sciences-Birth-Cohort study will provide a comprehensive assessment of risk factors and biomarkers for HEU infants' adverse outcomes. This will ultimately help developing strategies to mitigate effects of maternal HIV, early-life ART exposures and comorbidities on infants' mortality and morbidity. TRIAL REGISTRATION:ClinicalTrial.gov Identifier: NCT04087239 . Registered 12 September 2019.

SUBMITTER: Duri K 

PROVIDER: S-EPMC7532096 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

The University of Zimbabwe College of Health Sciences (UZ-CHS) BIRTH COHORT study: rationale, design and methods.

Duri Kerina K   Gumbo Felicity Z FZ   Munjoma Privilege T PT   Chandiwana Precious P   Mhandire Kudakwashe K   Ziruma Asaph A   Macpherson Andrew A   Rusakaniko Simbarashe S   Gomo Exnevia E   Misselwitz Benjamin B   Mazengera Lovemore Ronald LR  

BMC infectious diseases 20201002 1


<h4>Background</h4>Commencing lifelong antiretroviral therapy (ART) immediately following HIV diagnosis (Option B+), has greatly improved maternal-infant health. Thus, large and increasing numbers of HIV-infected women are on ART during pregnancy, a situation concurrently increasing numbers of HIV-exposed-uninfected (HEU) infants. Compared to their HIV-unexposed-uninfected (HUU) counterparts, HEU infants show higher rates of adverse birth outcomes, mortality, infectious/non-communicable diseases  ...[more]

Similar Datasets

| S-EPMC9844822 | biostudies-literature
| S-EPMC5580049 | biostudies-literature
| S-EPMC3491028 | biostudies-other
| S-EPMC6373310 | biostudies-literature
| S-EPMC6450609 | biostudies-literature
| S-EPMC6878239 | biostudies-literature
| S-EPMC6278160 | biostudies-literature
| S-EPMC6097170 | biostudies-literature
2016-03-11 | GSE79056 | GEO
2016-03-11 | E-GEOD-79056 | biostudies-arrayexpress